GenMark Diagnostics IncFind Ratings Reports
GENMARK DIAGNOSTICS INC's gross profit margin for the fourth quarter of its fiscal year 2016 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. GENMARK DIAGNOSTICS INC has strong liquidity. Currently, the Quick Ratio is 1.92 which shows the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 21.49% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY16||Q4 FY15|
|Net Sales ($mil)||14.89||13.19|
|Net Income ($mil)||-12.68||-8.78|
|Balance Sheet||Q4 FY16||Q4 FY15|
|Cash & Equiv. ($mil)||41.57||45.47|
|Total Assets ($mil)||80.32||70.67|
|Total Debt ($mil)||19.82||9.89|
|Profitability||Q4 FY16||Q4 FY15|
|Gross Profit Margin||65.97||71.32|
|Return on Assets||-62.99||-59.71|
|Return on Equity||-132.63||-86.83|
|Debt||Q4 FY16||Q4 FY15|
|Share Data||Q4 FY16||Q4 FY15|
|Shares outstanding (mil)||46.55||42.55|
|Div / share||0.0||0.0|
|Book value / share||0.82||1.14|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||262198.0||258865.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 15.85 indicates a significant premium versus the S&P 500 average of 3.00 and a significant premium versus the industry average of 4.72. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, GENMARK DIAGNOSTICS INC seems to be trading at a premium to investment alternatives within the industry.
|GNMK NM||Peers 41.69||GNMK NM||Peers 23.09|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
GNMK's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
GNMK's P/CF is negative making the measure meaningless.
|GNMK NM||Peers 23.68||GNMK NA||Peers 0.90|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
GNMK's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|GNMK 15.85||Peers 4.72||GNMK -12.87||Peers 126.02|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
GNMK is trading at a significant premium to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, GNMK is expected to significantly trail its peers on the basis of its earnings growth rate.
|GNMK 12.27||Peers 4.96||GNMK 25.02||Peers 14.58|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
GNMK is trading at a significant premium to its industry.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
GNMK has a sales growth rate that significantly exceeds its peers.